The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.

Novartis50 enrolled

Overview

Conduct disorder is a group of psychiatric symptoms that can include clinical characteristics of impulsivity and aggressive behavior. This study will investigate the efficacy a safety of oxcarbazepine in the treatment of adolescents with conduct disorder.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Conduct Disorder

Interventions

OxcarbazepineDRUG

Eligibility

Sex: ALLMin age: 6 YearsMax age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * History of conduct disorder, oppositional defiant disorder, and disruptive behavior disorder not otherwise specified * Score \>8 on the Impulsivity Rating Scale Exclusion Criteria: * Other serious medical or psychiatric conditions excluding conduct disorder, oppositional defiant disorder, and disruptive behavior disorder not otherwise specified * Treatment with antiepileptic medications Other protocol-defined inclusion/exclusion criteria may apply.

Outcomes

Primary Outcomes

Percentage reduction on Impulsivity Rating Scale (IRS)

Secondary Outcomes

Percent reduction in the Modified Overt Aggression Scale (MOAS)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.